MET and cancer: c-Met, known as hepatocyte growth factor receptor, orchestrates cell motility, invasion, and metastasis by activating signaling pathways such as Ras/MAPK, PI3K/Akt, and JAK/STAT, aberrant activation of which is linked to diverse cancers, notably driving invasive and metastatic growth, rendering c-Met a prominent therapeutic target, with multiple inhibitors devised to counter its oncogenic activity in cancer therapy.165